Key Highlights

• Barinthus Biotherapeutics shareholders approved all proposals at its 2026 Annual General Meeting, with 17,549,280 ordinary shares represented by proxy.

• A reverse stock split remains an option to address the bid price deficiency if needed.

Shareholder Meeting Outcome

Barinthus Biotherapeutics PLC (NASDAQ: BRNS) disclosed that its 2026 Annual General Meeting concluded with all items on the agenda receiving shareholder approval. The quorum was satisfied by 17,549,280 ordinary shares, each carrying a nominal value of £0.000025, presented in person or via proxy.

Voting Participation Details

A total of 40,848,893 ordinary shares held voting rights at the meeting. Although not every share was represented, the 17,549,280 shares present or proxied met the threshold required for valid corporate action under the company’s articles.

Nasdaq Compliance Deadline Extended

On June 30, 2026, Nasdaq notified Barinthus Biotherapeutics that it would be granted an additional 180‑day window to satisfy the Bid Price Requirement pursuant to Nasdaq Listing Rule 5450. The revised compliance deadline is set for December 28, 2026, giving the company further opportunity to bring the ADS bid price back above the $1.00 per share minimum. This transition does not alter trading mechanics but reflects a different tier of listing standards.

Bid Price Recovery Plan

Barinthus Biotherapeutics indicated it will continue to monitor its ADS price throughout the extension period. If the closing bid price equals or exceeds $1.00 per share for ten consecutive business days, compliance will be deemed restored. Management also noted that a reverse stock split could be considered should other actions fail to lift the price.

Potential Delisting Risks

Should the company not achieve compliance by the December 28, 2026 deadline, Nasdaq may issue a delisting notice. The firm would have the right to appeal the decision before a Nasdaq hearings panel, though there is no guarantee of continued listing if the bid price remains below the required level.

Sector Context and Investor Considerations

Barinthus operates within the biotechnology sector, where share price volatility is common due to clinical trial outcomes and regulatory developments. Investors should remain alert to forthcoming disclosures, including any corporate actions intended to address the bid‑price shortfall, as well as broader industry trends that could influence market perception of the company’s ADSs.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.